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on re-consent in a longitudinal biobank
Mary Dixon-Woods1* , David Kocman2, Liz Brewster3, Janet Willars2, Graeme Laurie4 and Carolyn Tarrant2Abstract
Background: Biomedical research increasingly relies on long-term studies involving use and re-use of biological
samples and data stored in large repositories or “biobanks” over lengthy periods, often raising questions about
whether and when a re-consenting process should be activated. We sought to investigate the views on re-consent
of participants in a longitudinal biobank.
Methods: We conducted a qualitative study involving interviews with 24 people who were participating in a
longitudinal biobank. Their views were elicited using a semi-structured interview schedule and scenarios based
on a hypothetical biobank. Data analysis was based on the constant comparative method.
Results: What participants identified as requiring new consent was not a straightforward matter predictable by
algorithms about the scope of the consent, but instead was contingent. They assessed whether proposed new
research implied a fundamental alteration in the underlying character of the biobank and whether specific projects
were within the scope of the original consent. What mattered most to them was that the cooperative bargain into
which they had entered was maintained in good faith. They saw re-consent as one important safeguard in this
bargain. In determining what required re-consent, they deployed two logics. First, they used a logic of boundaries,
where they sought to detect any possible rupture with their existing framework of cooperation. Second, they used
a logic of risk, where they assessed proposed research for any potential threats for them personally or the research
endeavour. When they judged that a need for re-consent had been activated, participants saw the process as way
of re-actualising and renewing the cooperative bargain.
Conclusions: Participants’ perceptions of research as a process of mutual co-operation between volunteer and
researcher were fundamental to their views on consent. Consenting arrangements for biobanks should respect the
cooperative values that are important to participants, recognise the two logics used by research volunteers, and
avoid rigidity. Agility may be favoured by tiered consent combined with strong oversight mechanisms; this
approach requires evaluation.
Keywords: Biomedical research, Human subjects research, Informed consent, Research ethics, Social science
researchBackground
Biomedical research increasingly relies on long-term
cohorts and clinical registries involving use and re-use of
biological samples and data stored in large repositories
or “biobanks” over lengthy periods [1]. Such projects
characteristically seek to create enduring resources for
multiple future research endeavours that may not be
specified fully in advance. Accordingly, the exact* Correspondence: md753@medschl.cam.ac.uk
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not be fully anticipated at the outset: the precise studies
to be undertaken may be defined over time, and may
evolve in unforeseen ways as new research ideas, uses
and possibilities are imagined and the available technolo-
gies, collaborations, sharing arrangements and analytic
methods change. These longitudinal projects complicate
traditional forms of consent to research that have tended
(in practice at least) to treat consent as one-off, project-
bound event where the aims and procedures of each in-
dividual study can be explicitly described up front [2–4].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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deal with the ethical dilemmas associated with biobank-
ing consent [5]. They range from models that treat the
initial consent as open-ended, unrestricted permission
through to more dialogic, consultative models that visu-
alise consent as an ongoing negotiated process between
participants and researchers [6]. One widely used ap-
proach has been to obtain so-called “broad consent”, a
term defined in different ways in the literature [7–9].
We use “broad consent” here to refer to initial consent
that is both to biobank participation and also to mul-
tiple, as yet not fully defined, uses that are minimally
restricted as long as they fall within a “framework for
future research of certain types” [10]. Hansson and
colleagues suggest that as long as “the information
covers all the issues that are relevant for a person’s
choice, then that person’s consent is appropriately in-
formed”[7]. Though debate and contestation about the
ethics of broad consent have persisted [4–6] a recent US
National Institutes of Health (NIH) workshop endorsed
broad consent [11], which is defined as “consent for an
unspecified range of future research subject to a few
content and/or process restrictions. Broad consent is less
specific than consent for each use, but more narrow
than open-ended permission without any limitations
(i.e., “blanket” consent).” The statement identifies the
benefits of broad consent, but also emphasises that it re-
quires robust oversight, communication with donors, en-
forcement of standards, and evaluation. This position
makes clear that broad consent is not a “free ride”
for researchers: it is conditional on ongoing oversight
(through, for example, ethics committees/institutional
review boards and other mechanisms of governance)
to provide safeguards for participants’ interests and
other important values.
In this article, we focus specifically on one of these
safeguards: that of re-consent. Re-consent can be defined
as an action in which a research participant makes the
decision to participate in a study once again, or consent
to new elements of an existing study: “the process of
seeking participant consent to change or update their
existing consent to allow their samples and data to be
used in a different way from that which was originally
agreed” [3]. Re-consent can be readily distinguished from
re-affirmation, where the intention is simply to express
willingness to abide by a decision already made [12].
Situations where a re-consent process may be consid-
ered include those where an initial broad consent cannot
defensibly be relied upon because of features of pro-
posed future use are sufficiently novel or mark a signifi-
cant departure from the terms on which the consent
was originally given; where an initial specific consent
does not cover a future intended use; where proposed
modifications to projects appear to be beyond the scopeof the original consent; where it is proposed to revisit a
group of participants for whom a study has been dor-
mant for some time, or when paediatric participants
reach adulthood [13]. The data-sharing policies recently
developed by large research funders are an example of
where a re-consent process might, in principle, be trig-
gered. For instance, the US National Institutes of Health
(NIH) now require all researchers who receive NIH
support to conduct genome-wide association studies to
submit de-identified data to the database of Genotypes
and Phenotypes (dbGAP), a centralised clearinghouse
for study data. Data from many cohorts funded by NIH
were established long before this rule was introduced,
and thus did not anticipate sharing of data in this way.
Re-consent is not, however, always a straightforward
solution [14]. Some of the difficulties are practical, and
include possible large costs, problems in contacting
research participants (for example, because of missing or
incorrect contact information), and non-return of re-
consent forms. These problems and others may result in
the attrition of volunteers and the undermining of re-
search activities [8, 15]. Also non-trivial is the potential
for a re-consent process to trigger distress, anger, or
other emotional reactions linked to perceptions of
violations of privacy or breach of trust [12], the possibil-
ity that existing participants may withdraw consent
altogether, and the risks that the integrity of a cohort
could be undermined by having multiple consents for
different purposes from different participants.
The question of what an ethically sound re-consent
process would look like then arises. It clearly requires
mechanisms for making decisions about when the limits
of an original broad consent are reached as well as sys-
tems for ensuring that any procedures used to seek new
consent are well-designed, operate efficiently, and are
recognised by stakeholders as fair, reasonable, respectful,
and attentive to their interests. The latter are especially
important requirements given evidence that cooperation
with the research enterprise is generally secured through
participants’ beliefs in the wholesomeness and public
value of the research endeavour, their trust in the insti-
tutions and individuals who recruit them as participants,
and their expectations about how research is conducted
and regulated [16–18]. Ensuring that a process recog-
nized as legitimate is in place is also fundamental to en-
suring the “social license” or legitimacy for the research
enterprise more broadly [19, 20].
It is therefore especially critical that the basis of partic-
ipants’ views on re-consent be well understood; insights
into why people reason in the way they do is crucial to
respecting their wishes [16, 21]. Yet, while participants’
views on broad consent have been studied extensively,
much of the debate to date on re-consent has involved
professional groups with a stake in these processes, such
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corpus of empirical studies is beginning to emerge
that has examined the views of participants them-
selves on re-consent in areas such as cancer genetics
research [22, 23] and twins research [24], but the literature
remains small. How participants reason about re-consent
in the context of longitudinal studies involving personal
medical data and biological samples remains under-
researched. In this paper we report a study that sought to
investigate the views on re-consent of participants in a
longitudinal biobank, with a particular interest in examin-
ing how people reason about when a need for re-consent
should be triggered.Methods
Our study design was a qualitative interview study,
for which ethical approval was obtained as well as
consent from each participant (see further details at
end of manuscript).
Semi-structured interviews were conducted with 24
participants in Generation Scotland, a biobank of human
biological samples for medical research that has been
funded since 2003 as a partnership between the Scottish
University Medical Schools and the Scottish National
Health Service (NHS). It includes over 30,000 volunteers
who provide samples and data for research purposes and
are followed over time [25]. Generation Scotland uses a
model of broad consent combined with governance that
was developed using a participatory process during its
planning and recruitment phase by a scientific commit-
tee reporting to an Independent Scientific Advisory
Board. The Generation Scotland Executive is now re-
sponsible for, inter alia, the governance arrangements,
accountability to the public, the scientific rationale and
scope within the broad consent given by participants,
consideration of any relevant ethical issues, and the con-
ditions under which researchers will be given access to
derived data, project data and samples collected by
Generation Scotland. An Access Committee reviews all
applications to use Generation Scotland resources, with
responsibility for ensuring that any application to
conduct a project conforms to the consent and ethical
approval obtained.
In our interviews we did not seek specifically to ex-
plore participants’ experiences and views of Generation
Scotland, except insofar as we asked them to describe
their recruitment to the resource. The main focus of
the interviews was on using their experiences as long-
term volunteers to consider scenarios based on a hypo-
thetical biobank relating to heart disease, with the aim
to determining under what circumstances they would
view a re-consent process as necessary and what form
it should take.Only those who had previously agreed to be contacted
about further studies by Generation Scotland were eli-
gible for inclusion. In order to comply with data protec-
tion and ethical requirements, the recruitment process
was managed by Generation Scotland. Invitational letters
were sent by Generation Scotland to 90 volunteers. We
stratified the sample according to responses to an exer-
cise conducted by Generation Scotland where partici-
pants were asked for reconsent to transfer abroad of
data and samples, contacting 37 who replied positively
to this request, 37 who replied negatively, and 16 who
did not reply to the request. The letters invited partici-
pants to take part in an interview study, and an enclosed
information sheet explained that the study was being
conducted by the University of Leicester and was confi-
dential. Participants were invited to return a reply slip to
the University of Leicester; respondents were contacted
by a Leicester researcher. Those who agreed took part in
a one- hour telephone interview that was digitally
recorded, transcribed verbatim and fully anonymised.
Informed consent was obtained from all participants.
The prompt guide used in the interviews was based on
review of the literature and discussions within the pro-
ject team and its collaborators. It sought to ensure some
consistency and comparability across interviews, but was
used flexibly in individual interviews. The first, very
brief, part of the interview comprised questions about
participants’ actual experiences in Generation Scotland
(their motivations to participate, recollections of consent
and re-consent processes). They were also asked in gen-
eral terms about their views of an optimal re-consenting
process most likely to safeguard their trust and well-
being. Participants were not asked in detail about their
responses to the re-consent exercise conducted by
Generational Scotland, beyond asking them whether
they remembered the exercise and, if they did, whether
they had re-consented. In the second and more substan-
tive part, participants were asked to discuss participation
in a hypothetical biobank called “Heart of Scotland”.
Described to participants, the hypothetical project was
modelled on Generation Scotland’s broad consent and
governance model and other characteristics: it was run
by a publicly-funded institution, collected data from
people over time, and anonymised and securely stored
all data. Unlike Generation Scotland, however, it focused
solely on cardiac research, to enable exploration of peo-
ple’s perceptions of the boundaries of projects. Partici-
pants’ views were sought on eight hypothetical scenarios
that covered a range of possible alterations to the
original consent, including changes of broad aims (e.g.
extending beyond cardiac research to include cancer re-
search), specific studies (e.g. involving access to new
types of data) and changes to research governance (see
Table 1). These scenarios were devised to include
Table 1 Scenarios used in interviews
Scenario 1: Involvement of commercial company
A new blood sample screening is invented by a commercial company.
The inventors think this will make it possible to detect who is more
susceptible to heart disease at a much earlier age than is now possible,
but the device needs to be tested further before they can be sure. If it
works, it is likely to make the company a lot of money. They would like
to put an application in to use the Heart of Scotland data and samples
to test it further.
Scenario 2: Brain research
A new screening test is developed which the inventors think will make
it possible to detect who is at risk of developing dementia at a very
early age (30). At the moment there are no treatments that can fully
prevent or treat dementia. It may be possible to support people better
if they are known to be at risk, but it could also mean that people
detected early live for a long time with unwanted knowledge and could
suffer discrimination. The consent for Heart of Scotland does not
mention diseases related to the brain; it only covers heart disease.
Scenario 3: Educational achievement and diet research
Let’s say a group of researchers want to use the Heart of Scotland
resources to study educational achievement and how it is affected by
diet. There is no particular focus on heart disease, but the researchers
think that the database can provide them with the answer they need
without having to set up a whole new study.
Scenario 4: Cross checking with police records
Heart of Scotland is now approached by other researchers. They are
trying to do research on a particularly sensitive area relating to heart
disease – they want to know if a history of crime in the family predicts
outcomes of heart disease. They therefore want to check police records
against Heart of Scotland data.
Scenario 5: Human embryos research
Now, let’s imagine Heart of Scotland is approached by researchers
wanting to use biological samples in research involving human
embryos. In line with UK law, licensed research can only take place on
embryos up to 14 days.
Scenario 6: Data sent overseas
Heart of Scotland can allow access to anonymised data and samples to
approved groups of researchers abroad.
Scenario 7: Feedback on personal health issues
When Heart of Scotland was set up, it was made clear to participants
that they would not get any feedback on clinical relevant findings. For
example, if it was discovered that a person had a genetic mutation that
meant that were at high risk of breast cancer, they would not be told
by Heart of Scotland. A change in this policy is proposed.
Scenario 8: Cancer research
Let’s imagine that Heart of Scotland has been running for 10 years. A
change in funding means it is now being asked to use its samples and
data to study cancer as well as heart disease.
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were based on review of the literature and discussions
within the research team and its collaborators to identify
a range of exemplars of potentially contentious issues.
Analysis of interview data was based on the con-
stant comparative method [26]. This involved iteration
between the developing analysis and data, supported
by regular team discussions and sensitising constructs
derived from the literature. The emerging categories
were organised into a framework and used to code
and index the transcripts using NVivo software.
Categories were continually checked and modified toensure an adequate ‘fit’ with the data, whilst also ac-
counting for deviant cases.Results
Of the 90 Generation Scotland volunteers contacted, 24
consented to take part in this interview study (14 men
and 10 women). Participants were between 32 and
81 years old, with a median age of 58 years. A quarter of
participants were over 65 years. Participants’ occupa-
tional backgrounds were varied; just over half reported
secondary level as their highest achieved educational
attainment. Just over half (13) recalled the re-consent
exercise conducted by Generation Scotland and all of
these indicated that they had given re-consent. The
remaining 11 did not remember the exercise or whether
they had given re-consent.Motivations to participate
Consistent with the findings of previous research on bio-
banking, participants reported that the most powerful
motivator for their volunteering both in the Generation
Scotland project and the hypothetical Heart of Scotland
project was the opportunity to contribute to the public
good: participation was presented as altruistically-driven,
and as offering, among other things, personal gratifica-
tion or “warm glow”.
You just want to be part of something, and if any way
you can improve things, so anything like that, long
term, it’s beneficial to other people, I tend to go for.
(008)
Some participants reported a generalised willingness
to contribute to advancing medical knowledge and did
not distinguish any particular beneficiaries; others
focused on specific classes of beneficiaries (such as the
people of Scotland).
I just thought that it was a good thing to do […] to
improve the quality of care and the early diagnosis of
heart problems [and] basically to help your fellow
man. (003)
It was looking at things about Scotland, and that was
the main reason I would have done it […]. I wouldn’t
have been so keen if it hadn’t been Scotland. (002)
Beyond a sense of contributing to public good, some
participants also identified the possibility of more personal
benefit, for example expressing hope that their children
and grandchildren could benefit from advances in medical
knowledge. Some also referred to the health check and
genetic testing undertaken as part of the research, which
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health.
Because I do have heart problems, […] my father had
heart problems, and there’s been various other members
of family that, the upper generation that have had
strokes and heart problems, so it would be of interest to
me to see how I could have avoided it[…] It would
probably benefit my children or their children. (001)
I think it would be a mixture; there’d be actually a few
factors. One would be curiosity, two would be some
kind of altruism in feeling that it might help research
on heart conditions and thirdly there might be an
element of self-interest in so far as, if all these things
are being done to you maybe in the course of that
something would crop up that would actually need to
be looked at. (009)
Warrants of trust
The desire to contribute to the public good (or gain
some personal health benefit, direct or indirect) was not
unconditional. Participants sought warrants of trust to
reassure them that enterprise in which they were being
asked to participate was a wholesome one with the
proper values and safeguards in place, and that they
were not being gullible or exposing themselves to risk in
agreeing to contribute. In this, the consent process had a
critical practical and symbolic role.
I remember being told it was confidential […] what
was going to happen, and how that information would
be used in the future. (002)
Having it clearly defined as to what is going to happen
and what further things are going to happen, and
what is not, certainly for me what will not happen.
And being able to ask the question. (003)
Though most (22 of 24) participants could remember
few of the specific details in the consent process for
Generation Scotland, they reported a strong sense of
certainty that there must have been a proper consent
process in place. They were adamant that the process
would have been adequate, otherwise they would not
have consented. Rather than the specifics of consent
forms, what was important to the volunteers was their
understanding of the cooperative bargain into which
they had entered.
It would have seemed very sensible and very
confidential […] or I wouldn’t have signed it […] it
didn’t stand out in my mind as anything that I needed
to worry about. (007)Though they were clear that their consent was in
support of a worthwhile endeavour and that the proper
assurances about the conduct of the research were in
place, they were equally clear that they did not see their
consent to biobank participation as offering an “open
ticket” to researchers to do whatever they wanted with
the samples and data that had been volunteered. They
did not, in general, regard themselves as having perman-
ently relinquished all rights and interests in their data
and samples.
I didn’t think it would be used unless I gave my
permission [for it] to be used, other than the
procedures that I went through. (001)
Without the right protections, some participants feared
that what they understood as a relationship of cooperation
with researchers might be jeopardised. For instance, they
worried that researchers might, intentionally or unwit-
tingly, stray beyond what participants understood as the
acceptable limits to the scope of the research, leaving
them feeling exploited, potentially damaging researchers’
reputations, inhibiting volunteers from taking part or
causing existing participants to consider withdrawal.
I think it’s very important you know when a piece of
research like this is carried out that in no way is it a
Trojan horse. It must not be - too often these things
are launched and then things like such as this can be
used in quite a knowing way, that leave ends that
might have eluded or escaped the perception of the
participants. Nevertheless it’s got to be true to […] its
stated aims and purposes. [It] must be explicit and
comprehensive and any kind of exploitation of the
ignorance or innocence of the participants must be
avoided at all costs. (009)
The logic of boundaries and re-consent: continuities and
ruptures
One important way in which participants determined
the acceptable limits of their consent was by assessing
the extent to which proposed new research moved
beyond, or sat within, their existing framework of co-
operation. These judgements were grounded in what we
dub a logic of boundaries. Where participants could
identify continuities and alignments between the original
consent and any newly proposed research, existing
frameworks of cooperation remained intact; since the
basis of their initial consent was still secure, re-consent
was not judged to be required.
I suppose it all comes back to the initial decision, that
if you decide to participate in something then I wouldn’t
have any objection really about any type of research
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all one in the same thing, providing it for the initial
study – or the reasons that I would have participated -
would still apply, regardless of what type of research
was being carried out. (Scenario 2: 006)
Thus, when participants assessed new research as
broadly within the boundaries of their original consent,
they did not see that further permissions or re-consent
would be needed for specific projects – though there
was variability in individual responses as to what exactly
would comprise the limits of these boundaries. For some
participants, the addition of a new disease focus would
not require additional consent, since they saw the ori-
ginal consent as enabling improvements in quality of life
through research. Similarly, some participants identified
continuity of the boundaries of their original consent
where their motivations were to reduce risk of disease
for future generations, or where they saw their protec-
tions (such as anonymization) remaining intact.
I don’t think [re-consent] is required […] it’s
fundamental actually to find that knowledge that if
there is a risk of dementia then it should be treated,
because people with dementia, they don’t have a life
(Scenario 2: 021)
No I don’t have any difficulty with that at all, I don’t
think there is any need to ask for that permission
again (…) it’s obviously an important thing if you can
affect how well or badly somebody, some of your
youngsters are going to be affected then it’s worthwhile
(Scenario 3: 004)
They should just go ahead. They shouldn’t need any
permission, they should just go ahead, [it is still
anonymised]. (Scenario 4: 014)
Sometimes, however, participants identified ruptures
between their frameworks of cooperation and proposed
new research activities described in the scenarios. These dis-
continuities occurred when participants deemed the new
elements of research to be overstepping the boundaries of
the original agreement. These ruptures might occur in two
ways: first, some fundamental change in the character of the
biobank and the principles governing the cooperative bar-
gain might be identified. Some participants saw such shifts
as occurring, for example, when it was proposed to expand
the remit of a biobank set up for heart research to include
cancer and brain research, to allow data sent overseas as
opposed to research being carried out in the UK, to widen
access to data and samples to commercial companies rather
than limiting it to publicly-funded research, or to extend
into areas seen as not truly “medical” research.[To me] it’s a purely medical reason that they’re doing
studies [and] I don’t see that the [new research] there
is particularly medical. (Scenario 3: 019)
A second way in which a rupture might occur was when
a specific project was seen to be no longer covered by the
original consent. Here, judgements were made about the
extent to which the new project was “in scope”.
I just think [diet and educational achievement is] a
whole different thing. You know I think you’d need
permission to do that. (Scenario 3: 005)
A view that a new consent was needed – either to the
nature of the biobank or for a specific project - was not
necessarily associated with unwillingness to participate
in the new research: it was instead an indication that the
bargain between researchers and participants needed to
be re-affirmed. For example, one of the scenarios used
in the hypothetical Heart of Scotland project involved a
commercial company’s involvement in research, though
commercial involvement had been excluded from the
original consent. Some participants expressed no anxie-
ties about commercial interests, but still felt re-consent
should be sought by researchers.
The original consent said that there’d be no
companies. […] So I think in that case if it was
potentially going to a company who was likely to make
a large profit, but could have the breakthrough, I think
that should be separate permission. (Scenario 1: 015)
The logic of risk
A second way in which participants made judgements
about whether re-consent might be required involved a
logic of risk. When drawing on this logic, participants
considered how far new research might be seen as ethic-
ally questionable – not just by them as individuals, but
by broader publics – and thus pose risks to legitimacy.
When participants drew on this logic, it dominated over
all other considerations.
I mean it only takes one person just to say oh, that’s
not right, and then the whole sort of research thing
could be in jeopardy […] if it came out that the
data had been used for things that initially wasn’t
asked for permission for, it could put everything else
‘all to cop’. (008)
That’s a hugely personal and emotional issue. […]
Yeah, you imagine if someone was to be told that at the
end of the day when they didn’t know they were involved
in [human embryo research], I think some people might
feel they’ve been exploited. (Scenario 5: 013)
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research issues that could potentially generate concerns,
but participants varied in which they saw as activating
logics of risk. The ‘riskiest’ scenario (the scenario that
stimulated use of the logic of risk in the greatest number
of participants) was one involving hypothetical access by
researchers to police records, where 17 of the 24 partici-
pants reported that their reasons for requiring re-consent
were rooted in judgements of risk. The least risky research
scenario described hypothetical research comparing edu-
cational achievements and diet, with only four participants
drawing on the logic of risk.
When the logic of risk was deployed, participants
typically highlighted issues that they saw as requiring
researchers to seek an endorsement from them as their
partners. Participants were, for example, more likely to
see as risky those scenarios that they judged as poten-
tially breaching anonymity, which they saw as one of the
key pillars of the cooperative bargain.
Yes, [re-consent is] definitely [needed]. Again I think
it’s encroaching on people’s private life rather than
their health life. I think you would have to ask the
particular person. (Scenario 4: 005)
Variability in orientations towards research cooperation
and re-consenting
All participants were long-term volunteers in medical
research and tended to approach the prospect of being
asked to cooperate in new research positively; the logic
of boundaries rather than the logic of risk mostly acted
as their default logic, in part because of their faith in the
warrants of trust governing the project.
Maybe I’m naïve person, I don’t know. But I think if
I’ve signed up to something then, unless it’s something
horrific that is going to be terrible for mankind, I don’t
need to be asked again and again for permission to
use it. You’re a reputable organisation, otherwise you
wouldn’t be doing any of this work, and therefore I
shouldn’t have any fears as to how it’s going to be
used. (Scenario 2: 004)
However, individuals varied in their positions on dif-
ferent scenarios and the principles they used to arrive at
those positions. No participant approached the hypo-
thetical scenarios by consistently deploying either the
logic of boundaries or the logic of risk only. Individual
participants varied in how they used the two logics, how
they balanced them, and what issues drew their attention
in reaching judgements. No scenario was judged consist-
ently across all participants. This suggests that no dis-
tinct ‘types’ of participants or consistency of response
can be discerned. Although the hypothetical scenariosprovided as part of the study deliberately involved ele-
ments of novelty, or issues deemed to be widely judged
as ethically controversial, variations in participants’ re-
sponses indicated that no research scenario generated a
monochromic response.
Handling re-consent
Re-consent was described by participants as a critical elem-
ent of the cooperative bargain. It was understood not only
as offering an opting-out mechanism when research scenar-
ios were judged unacceptable, but, perhaps more import-
antly, as a way to renew the foundations of cooperation.
Absolutely, they must [ask for re-consent], yes. I think,
this goes into the area of human rights, people’s
rights and their liberty, absolutely, you know.
(Scenario 4: 002)
I think that’s moving quite a bit away from the consent
originally given […] so I would be happier in that
situation to be asked to re-consent. (Scenario 2: 010)
Participants offered a number of recommendations on
feasible and acceptable consenting and re-consenting ar-
rangements. They were explicit that practices of consent
must retain meaning and purpose: for them, consent
was an institutionalised space for the exercise of partici-
pants’ agency in the cooperative bargain. Accordingly,
most participants (21 out of 24) emphasised the need for
initial consent to be sound, and suggested ways in which
the process could be improved, specifically by enabling
participants to register individual choices. They felt that,
offered a menu of possible consents (rather than a single
broad consent), they could indicate both their prefer-
ences for the principle of research participation and any
extensions or exceptions they might wish to make
known at the outset. Participants understood such
choices as ‘informed’ because they would be given infor-
mation on what various types of research would and
would not involve.
I’m happy for other things, but maybe not that one, if
you know what I mean. You could probably have –
you know like you have with your donor card – you
can have this, this or this, but not that. They can have
my heart, they can have my liver, but they can’t have
my eyes. So you can… possibly have a tick box to say
yes, I can be used for this, can be used for that, but not
for this, this or this. (017)
Once the initial consent was in place, oversight mech-
anisms were seen as critical to ensuring the ongoing
monitoring of the boundaries of the consent and of any
risks.
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in because you can see that there is an authority
observing the study and that any point they might say,
well you’re stepping beyond the first consent. I think
that’s good. (015)
Participants perceived that oversight bodies would,
where appropriate, make decisions on when new
consents might be needed, but would not necessarily be
enabled to authorise projects on their behalf. Particularly
where the logic of risk was engaged, participants re-
ported that new consent would still be required. Retain-
ing the right to withdraw entirely was also identified as
an important right to be safeguarded:
Certainly if it’s going down the line of embryonic study
and police stuff, no you need to contact the people.
(003)
The most important thing to say is this whole process
can be stopped and brought to a close and the
information withdrawn or cancelled, as soon as the
volunteer feels uncomfortable with it. I think that’s the
most important thing, because I would not sign up if I
felt for a second that I was joining a kind of
unstoppable programme. I wouldn’t do it. I must know
that I am free to stop (009)
Participants offered suggestions on how the member-
ship and functioning of oversight bodies might be opti-
mised. They were especially keen that they included
individuals who were themselves participants and had a
stake in the outcome of decisions.
It’s good to have a committee or whatever that’s there,
that understands that sort of thing, and that says
hang on a minute. And I think it’s good that a person
that’s involved in the research can know that there’s, in
the background there’s a committee that’s actually just
making sure that everything is 100% proper. (004)
I think there probably has to be some legal input I
would imagine, from some sort of legal background,
ethics, you know, ethics, but I think participant
members would be very useful. (002)
Discussion
A model of broad consent plus oversight remains popular
among large-scale biobanks. Though some commentators
have argued that broad consent is ethically unsound, par-
ticipants in our study did not see it that way. Instead, they
understood and accepted that it might not be possible to
anticipate all possible uses of samples and data at the
outset of a longitudinal study: what mattered most to
them was that the cooperative bargain into which theyhad entered was maintained in good faith. The relevant
question for them was therefore one of how to protect this
bargain. Participants saw re-consent as one important
safeguard, valued as a way of demonstrating respect for in-
dividuals’ values and preferences and as a means of secur-
ing the legitimacy of the research endeavour – its social
licence - more broadly. What participants identified as re-
quiring new consent was not, however, a simple matter
predictable by algorithms about the scope of the consent,
but instead was contingent. They assessed whether pro-
posed new research implied a fundamental alteration in
the underlying character of the biobank and whether
specific projects were within the scope of the original con-
sent. Participants used two distinct forms of reasoning in
structuring their judgements about when and whether
they should be asked to re-consent: the logic of boundar-
ies, where they sought to detect any possible rupture with
their existing framework of cooperation, and the logic of
risk, where they assessed any potential threats for them
personally or the research endeavour as a whole. Partici-
pants were keen to maintain the meaning behind consent
as an ethical and purposeful practice, and proposed forms
of tiered initial consent followed by active monitoring of
need for re-consent as a way of assuring this status. When
they judged that a need for re-consent had been activated,
they saw the re-consent process as way of re-actualising
and renewing the cooperative bargain between researchers
and participants.
Our study does have some limitations. We had a re-
sponse rate of 26% which, while not atypical of this kind
of research, was not as high as we had hoped. Further,
we had no way of determining the representativeness of
our sample. Nonetheless, these findings are important
for the debate on the arrangements for consent and re-
consent, suggesting that no simple calculus can be
constructed to specify categories of research where par-
ticipants are likely to feel that re-consent is or is not be
required. This finding is consistent with previous
attempts to identify ‘controversial’ topics for which re-
consent may be required [27]. For instance, categorising
data use as ‘commercial’ or ‘non-commercial’ also does
not predict acceptability [28–30]. Developing categories
of types of participants is equally unlikely to be appro-
priate [31], and might lead to crises of representation
that could weaken rather than strengthen the coopera-
tive bargain. Clearly, however, some means of determin-
ing when re-consent is required is needed.
One answer might be to look to the law to provide the
rules. But, though law will always have a role in providing
a general framework of standards and enforcement, it can-
not provide the answer in most cases where the possibility
of re-consent arises [32]. Legal clarity on its own is
unlikely to secure trust: as work on the social licence to
operate has repeatedly demonstrated, going “beyond
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rules are also likely to introduce unnecessary rigidity. The
very nature of the biobank enterprise over time — an in-
herently uncertain and unpredictable process — means
that interpretations of the boundaries of original broad
consent will always be a fluid matter. As Hoeyer argues,
universal ‘solutions’ may be doomed to failure, and it may
be time to acknowledge diversity and its implications [31].
Participants in our study instead proposed an approach
that offered a form of informed flexibility. It would involve
a two-stage regime. First, rather than a single broad con-
sent, the initial consent would offer structured options
that would enable participants to choose not to allow
some uses of their sample and tissues from the outset.
This kind of regime is consistent with what has been de-
scribed in the literature as tiered consent [34]. It allows
participants to indicate whether they consent to all future
uses of their data and samples or to select from a menu of
categorical options — for example, declining data-sharing
outside a specific biobank. Previous studies have suggested
that tiered initial consent appears to be an approach
favoured by participants, providing a mechanism to re-
spect individuals’ preferences without imposing undue
burdens on researchers [34] – though not all agree [35].
A second stage would involve the possibility of consent
either for fundamental changes to the character of the bio-
bank or for specific projects deemed to be outside the
scope of the original consent. Participants in our study
were generally prepared to consider possible extensions to
the scope of their consent, but they often, as previous
studies have suggested, wanted to be asked and not merely
informed [36]. To some extent, this second stage shares
features with the model of dynamic consent proposed by
Kaye and others [37]. Dynamic consent seeks to shift con-
sent from a one-time, upfront process to one that runs
through the life-time of the biobank, and is intended to
create a more dialogic “ongoing relationship based on
trust and reciprocity” [5]. However, the specifics of how
such an approach would operate need considered atten-
tion [38]: the practicalities of managing dynamic consent
are non-trivial, and how they can be managed in ways that
ensure respect for and balance the interests of research
participants, researchers, and society at large is not always
clear [39]. Insisting that participants must consent anew
to each study – as implied by some (though not all)
models of dynamic consent - places considerable onus on
participants to police the contours of their own consent;
another risk is that it imposes a tyranny of choice, where
participants are faced with information overload and risk
of regret associated with having to choose between too
many options [10]. Yet new consent to each proposed
new use of samples and data did not seem to be what par-
ticipants in our study sought: instead, they wanted new
consent only when they perceived a breach in the terms oftheir original consent. A regime of agile consent that does
not necessarily incorporate all features of the dynamic
consent model might satisfy these requirements, and
should be tested empirically in future studies.
What is clear is that oversight mechanisms to determine
which studies appear to be candidates for a new consent-
ing process, based on the kinds of reasoning that partici-
pants themselves use, will be required. Consistent with
current practice in many biobanks, only those that appear
to go beyond the scope of the original consent or to intro-
duce risks would activate a new consenting process. How-
ever, in the model proposed by participants in our study,
decision-making about whether new consent is required
should assess not just the implications for individual par-
ticipants but also the social licence for a particular bio-
bank. Second, a critical feature of these oversight bodies is
that they should, as participants in our study proposed, in-
clude participant representatives who can foster the kind
of authentic research relationship where communication
and dialogue have prime importance. Third, participants’
motivations should be fully respected, so that any deci-
sions made should be accountable, justified, and clearly
non-exploitative. For a voluntary endeavour such as
research participation to thrive, the nature of the coopera-
tive bargain to be struck must be recognised and hon-
oured, and this is likely to require reciprocity and two-way
communication over repeated encounters [3, 20].
Conclusions
The question of how ethical obligations to research partici-
pants who have given broad consent to biosamples and
medical records to be used for research can be safeguarded
continues to attract attention. It is clear that no one-shot
magic bullets, legal or otherwise, will secure the cooperative
bargain that underpins participants’ engagement with bio-
banking research. Participants’ perceptions of research as a
process of mutual co-operation between volunteer and re-
searcher were fundamental to their views on consent. We
found variation in how participants applied the logics of
boundaries and of risk, suggesting that no calculus can
readily be constructed to predict straightforwardly what
might agitate concern. Our findings suggest that future
consenting arrangements should be sensitive to the co-
operative values that participants see as governing their re-
lationships with longitudinal biobanks, recognise the two
logics used by research volunteers, and avoid rigid models
that assume monochromic responses. Views of participants
in our study suggest that one model that would benefit
from further evaluation would use flexible approaches,
where, for example, tiered initial consent is combined with
oversight mechanisms to ensure that possible new studies
or alterations to the character of the biobank are given
proper scrutiny, with participant involvement, to determine
when new consent is needed.
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